CARTPT Genotype

Two people can eat the same diet and end up with very different waistlines, blood sugar, and cholesterol numbers. Part of that gap is wired into the genes that help regulate hunger and energy use. CARTPT (cocaine and amphetamine regulated transcript prepropeptide) is one of those genes, and a common variant in it has been studied in relation to how your metabolism responds to the carbohydrates on your plate, with effects that appear to depend heavily on diet quality.

This test reads a single inherited spot in your DNA called rs2239670. The result does not change over your lifetime. What changes is how you use it: knowing which version you carry can help you decide how aggressively to watch your blood sugar, your weight, and the quality of the carbs you eat.

What This Gene Actually Does

The CARTPT gene carries the instructions for a peptide signal involved in appetite control and energy balance. It is best known for its role in the brain, but the same peptide is also produced in pancreatic islet cells, where it influences insulin and glucagon release. Genetic variation in this gene has been studied as a possible contributor to obesity and metabolic risk in humans. The variant this test reads, rs2239670, has three possible forms: GG, AG, and AA. In the available research, AA carriers tended to show less favorable metabolic patterns, but mainly in the context of how their diet interacted with the genotype rather than as a stand-alone effect.

This is a research-stage genetic marker. It is not part of any standardized clinical screening guideline, and all human evidence comes from a single research group studying one cohort of 288 obese adults in Iran across multiple publications. The findings have not been replicated in other populations. Treat the result as one input into a bigger picture, not a verdict.

Metabolic Syndrome Risk

In a study of 288 adults with obesity, statistical modeling suggested that carrying the rs2239670 variant had a small direct effect on whether someone met the criteria for metabolic syndrome, a cluster of findings including high blood pressure, high blood sugar, abnormal cholesterol, and excess waist fat. The same modeling suggested an additional indirect association, in which carriers were more likely to eat higher glycemic index and glycemic load diets, meaning carbohydrates that spike blood sugar more sharply. Because the data are cross-sectional, this is a statistical pattern rather than proof that the gene causes people to choose particular foods.

What this means for you: if your result shows you carry the higher-risk version, the takeaway is not that you are doomed to develop metabolic syndrome. It is that the quality of the carbohydrates you eat may matter more for you than for someone with a different version of this gene.

Blood Sugar and Insulin Patterns

In the same group of 288 obese adults, gene-diet interaction analyses showed that AA carriers tended toward higher fasting glucose and higher HOMA-IR, a calculated score for insulin resistance, with patterns differing by sex and by diet quality. Sex-specific differences in appetite-related hormones, including alpha-MSH and AgRP, were also reported, again largely as interactions with diet rather than simple stand-alone genotype effects. These hormone differences hint that the AA version is associated with a less favorable hunger and energy-balance setup, particularly in obese individuals on lower-quality diets.

How Diet Quality Changes the Picture

The most useful finding for someone with this result is that diet quality genuinely changes the impact of the gene. Two diet scoring tools were tested. The Healthy Eating Index, or HEI, captures overall adherence to general healthy eating guidelines. The Diet Quality Index International, or DQI-I, captures a broader picture including variety, adequacy, moderation, and balance.

Among AA carriers in the obese cohort, higher DQI-I scores were linked to lower fat mass, lower body mass index, smaller waist circumference, lower fasting blood sugar, lower AgRP, and higher basal metabolic rate. The HEI score also interacted with the gene but did not fully erase the adverse pattern in AA carriers, who still had higher fasting glucose even when HEI scores were high.

What this means for you: if you carry the higher-risk version, the practical message is that overall diet quality, not just hitting a few rules, appears to matter most. A broader, well-balanced eating pattern looks more protective than a single-axis change like cutting one food group.

Carbohydrate Quality as a Pressure Point

In the obese cohort, statistical mediation analysis suggested that carrying the rs2239670 variant was associated with higher dietary glycemic index and glycemic load. Higher glycemic index in men was linked to higher LDL cholesterol, and higher glycemic load in women was linked to higher LDL and total cholesterol. This is a pattern observed in a cross-sectional sample, not proof that the gene drives food choices, but it points to where the variant appears to leave its biggest fingerprint on the lipid panel.

This is the cleanest place to act on the result. Glycemic index and glycemic load are modifiable through food choices. The evidence suggests that for people carrying the higher-risk version, the cost of frequent fast-acting carbohydrates may be higher than for the average person.

How to Read a Counterintuitive Result

It is possible to carry the higher-risk AA version and have perfectly normal labs, and it is possible to carry the lower-risk version and develop metabolic syndrome anyway. This gene variant nudges risk, it does not set it. The available studies were done in obese adults in a single Iranian cohort, so what shows up in lean, metabolically healthy people or in other populations with the same genotype is not well characterized. Read the result as a single tilt in a complex system, not as a diagnosis.

Your One-Time Result

Your CARTPT genotype is fixed at conception and does not change over time. There is no benefit to retesting unless the lab raises a question about variant call quality, in which case a confirmatory test by a different method may be warranted. What does need ongoing tracking are the downstream numbers this variant has been linked to: fasting glucose, HbA1c, fasting insulin, LDL cholesterol, triglycerides, and waist circumference.

The published CARTPT studies do not prescribe a specific monitoring schedule. As a general preventive-care approach, many clinicians use a baseline metabolic and lipid panel now, a follow-up at three to six months if you are making meaningful dietary or weight changes, and at least annual monitoring after that. The value of this genetic result lies in the decisions it sharpens over years, not in the test itself.

What to Do With an At-Risk Result

If you carry the higher-risk AA version, the productive next steps are not about your genes, they are about the numbers your genes may be pushing. Pair this result with a fasting glucose and HbA1c reading, a fasting insulin and HOMA-IR calculation, and a full lipid panel including triglycerides and LDL cholesterol. If you have not measured waist circumference and body composition recently, add those.

If those downstream numbers are already drifting in the wrong direction, the gene result gives you a reason to act sooner rather than waiting for a diagnosis. If they are clean, the result is a flag to keep them that way through diet quality and to retest at a cadence you and your clinician agree on. A clinician familiar with preventive cardiology or metabolic health is the right partner if multiple markers are abnormal.